Results 81 to 90 of about 44,698 (259)

Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo

Advanced Science, EarlyView.
Dual priming with minocycline and photodynamic priming reprograms the pancreatic tumor microenvironment to overcome chemoresistance. By suppressing DNA repair enzyme Tdp1, inducing photooxidative damage, and enhancing irinotecan delivery via light‐activated nanoencapsulation, this strategy remodels the tumor microenvironment and drives immune ...
Fernanda V. Cabral, Jose Quilez‐Alburquerque, Olivia Mooradian, Shivendran Vytheswarran, Badri Parshad, Girgis Obaid, Huang‐Chiao Huang, Tayyaba Hasan   +7 more
wiley   +1 more source

Scalable Engineering of Bio‐Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient‐Derived Models

Advanced Science, EarlyView.
Engineered extracellular vesicles displaying Ephrin‐B2 selectively target Ephrin‐B4–expressing ovarian cancer cells, enabling precise delivery in patient‐derived models. This scalable bio‐manufacturing platform reveals a versatile strategy to exploit Ephrin signaling for highly specific therapeutic payload delivery and motivates exploration of tailored
Nihar Godbole, Andrew Lai, Alexander Quinn, Marianne Gillard, Dominic Guanzon, Katherin Scholz‐Romero, Alexis Salas‐Burgos, Bastián Lillo Dapremont, Rohan Lourie, Naven Chetty, Richard Lobb, Kate Beecher, Amy E. McCart Reed, Kaltin Ferguson, Biao Sun, Yaowu He, John D. Hooper, Carlos Salomon   +17 more
wiley   +1 more source

Genetic Code Expanded T Cell for Controllable Immunotherapy

Advanced Science, EarlyView.
Our GCE‐CAR‐T cells enables tight, dose‐dependent, and function‐preserving control of CAR expression at the translational level through amber codon suppression and genetic incorporation of ncAA. ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy has demonstrated curative potential against hematologic malignancies, but its clinical application ...
Xue Wang, Yingao Gao, Yeyu Su, Yong Wang, Tao Liu   +4 more
wiley   +1 more source

High-throughput screening for optimizing adoptive T cell therapies

Experimental Hematology & Oncology
Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non-
Yuchen Zhang, Qinglong Xu, Zhifei Gao, Honghao Zhang, Xiaoling Xie, Meifang Li   +5 more
doaj   +1 more source

Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy

Cell Reports
Summary: Adoptive cell therapies are emerging forms of immunotherapy that reprogram T cells for enhanced antitumor responses. Although surface programmed cell death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) engagement inhibits antitumor ...
Xinran Wang, Lu Lu, Xiaochuan Hong, Lingling Wu, Chao Yang, You Wang, Wenwen Li, Yuanqin Yang, Dongqing Cao, Wen Di, Liufu Deng   +10 more
doaj   +1 more source

A good start of immunotherapy in esophageal cancer

Cancer Medicine, 2019
Considering the benefits of immunotherapy in advanced melanoma, non–small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is ...
Qian Zhao, Jinming Yu, Xue Meng
doaj   +1 more source

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

Advanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang, Shengxin Lu, Guangyong Zheng, Shensuo Li, Hongyu Chen, Mei Hong, Xiangru Zhou, Ruotian Tang, Ye Wu, Weidong Zhang, Dong Lu, Xin Luan   +11 more
wiley   +1 more source

A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates

Advanced Science, EarlyView.
Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao, Yan Deng, Jianjian Han, Yong Xie, Kai Bao, Lixin Ma, Lilong Liu, Wuxiang Mao   +7 more
wiley   +1 more source

PANX2 Suppresses Lung Adenocarcinoma Progression by Inducing Disulfidptosis and Enhancing Antitumor Immunity

Advanced Science, EarlyView.
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen, Zhao‐Yu Liu, Gao‐Wen Qu, Run‐Hao Zeng, Wen‐Xia Yao, Yong‐Bing Zhou, Xue Liang, Yu‐Xiong Lai   +7 more
wiley   +1 more source

Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC

Advanced Science, EarlyView.
Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang, Lin Ding, Yu Zhong, Haokang Feng, Linglong Huang, Waidong Huang, Chunqing Wang, Arne Östman, Beili Wang, Jian Zhou, Jia Fan, Wei Guo, Liang Wu, Yunfan Sun   +13 more
wiley   +1 more source